{"filing":{"accession_number":"0001140361-26-031671","cik":"0001444192","ticker":"GRCE","company_name":"Grace Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-04","primary_document":"ef20079559_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126031671/ef20079559_8k.htm"},"events":[{"id":25457,"run_id":23108,"accession_number":"0001140361-26-031671","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Grace Therapeutics entered into a securities purchase agreement on August 4, 2026, to issue 4,761,904 shares of common stock at $2.10 per share in a private placement offering, generating approximately $10 million in gross proceeds. The unregistered securities were sold under Section 4(a)(2) of the Securities Act and Rule 506, with 90-day lock-up restrictions, representing a material dilutive issuance to raise capital for the company's operations.","company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26292,"accession_number":"0001140361-26-031671","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Grace Therapeutics entered into a securities purchase agreement on August 4, 2026, to issue 4,761,904 shares of common stock at $2.10 per share in a private placement offering, generating approximately $10 million in gross proceeds. The shares were sold without registration under Section 4(a)(2) of the Securities Act and Rule 506, characteristic of a dilutive private placement. The company also imposed lock-up restrictions on itself (90 days from closing or 30 days after registration statement effectiveness), typical of PIPE-like transactions. This is material as it significantly dilutes existing shareholders and raises capital for the company's operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:46:36.413654+00:00","company_name":"","ticker":null,"filing_date":""},{"id":26293,"accession_number":"0001140361-26-031671","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Grace Therapeutics announced a $10 million private placement of 4,761,904 shares of common stock at $2.10 per share in an unregistered transaction under Item 3.02. The filing explicitly states the securities \"have not been registered under the Securities Act of 1933\" and are being issued in a transaction not involving a public offering. This is a classic dilutive equity issuance to raise capital, material to investors as it extends the company's cash runway to end of 2028 and represents significant dilution to existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:46:36.413654+00:00","company_name":"","ticker":null,"filing_date":""},{"id":26294,"accession_number":"0001140361-26-031671","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Grace Therapeutics announced a $10 million private placement of 4,761,904 shares of common stock at $2.10 per share in an unregistered securities offering. This is a classic dilutive equity issuance under Item 3.02 (or disclosed under Item 8.01 as here). The filing explicitly states the securities \"have not been registered under the Securities Act of 1933\" and are being sold in a private placement to new and existing investors. For a late-stage biopharma company with limited cash runway, this capital raise is material to investors assessing the registrant's financial position and dilution to existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:46:36.413654+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26292,"accession_number":"0001140361-26-031671","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Grace Therapeutics entered into a securities purchase agreement on August 4, 2026, to issue 4,761,904 shares of common stock at $2.10 per share in a private placement offering, generating approximately $10 million in gross proceeds. The shares were sold without registration under Section 4(a)(2) of the Securities Act and Rule 506, characteristic of a dilutive private placement. The company also imposed lock-up restrictions on itself (90 days from closing or 30 days after registration statement effectiveness), typical of PIPE-like transactions. This is material as it significantly dilutes existing shareholders and raises capital for the company's operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:46:36.413654+00:00","company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","filing_date":"2026-08-06"},{"id":26293,"accession_number":"0001140361-26-031671","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Grace Therapeutics announced a $10 million private placement of 4,761,904 shares of common stock at $2.10 per share in an unregistered transaction under Item 3.02. The filing explicitly states the securities \"have not been registered under the Securities Act of 1933\" and are being issued in a transaction not involving a public offering. This is a classic dilutive equity issuance to raise capital, material to investors as it extends the company's cash runway to end of 2028 and represents significant dilution to existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:46:36.413654+00:00","company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","filing_date":"2026-08-06"},{"id":26294,"accession_number":"0001140361-26-031671","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Grace Therapeutics announced a $10 million private placement of 4,761,904 shares of common stock at $2.10 per share in an unregistered securities offering. This is a classic dilutive equity issuance under Item 3.02 (or disclosed under Item 8.01 as here). The filing explicitly states the securities \"have not been registered under the Securities Act of 1933\" and are being sold in a private placement to new and existing investors. For a late-stage biopharma company with limited cash runway, this capital raise is material to investors assessing the registrant's financial position and dilution to existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:46:36.413654+00:00","company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","filing_date":"2026-08-06"}]}